ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
advertisementadvertisement
Gynecologic Oncology
Volume 109, Issue 2, May 2008, Pages 291-295
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (520 K)

  E-mail Article   
  Add to my Quick Links   
Bookmark and share in 2collab (opens in new window)
Request permission to reuse this article
  Cited By in Scopus (0)
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.ygyno.2007.10.026    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2007 Elsevier Inc. All rights reserved.

Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma

Sushil Beriwala, Corresponding Author Contact Information, E-mail The Corresponding Author, Devin Coona, Dwight E. Herona, Joseph L. Kelleyb, Robert P. Edwardsb, Paniti Sukumvanichb, Kristin K. Zornb and Thomas C. Krivakb

aDepartment of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA bDivision of Gynecologic Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Received 17 August 2007. 
Available online 1 May 2008.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Objective.

Intensity-modulated radiation therapy (IMRT) is a rapidly maturing technology that allows delivery of radiation dose in a more conformal manner by varying the radiation beams spatially or temporally. The purpose of the study was to assess the clinical outcome in patients with locally-advanced vulvar cancers treated using preoperative chemotherapy with IMRT.

Methods.

Eighteen patients with stage II–IVA cancer were treated with a modified GOG schema using 5-fluorouracil (5-FU) and cisplatin with twice-daily (BID) IMRT during the first and last weeks of treatment. Surgery was planned for 6–8 weeks post-treatment.

Results.

The median follow-up time was 22 months (2–60 months). Fourteen patients had surgery performed with pathological complete response (pCR) in 9 (64%) patients and partial response (pPR) in 5 patients. There were no recurrences in the 9 patients who achieved pCR whereas 3/5 with pPR had local recurrence (p = 0.027). Four patients did not have surgery: one patient died a week after treatment while 2 of the remaining 3 patients had local recurrences. Acute desquamative skin reactions in the vulva and perineum were seen in all patients. Three of the 14 patients who had surgery had prolonged wound complications requiring debridement. No patients had radiation-related acute or late toxicity of grade = 3. The 2-year cause specific and overall survivals were 75% and 70% respectively.

Conclusion.

Preoperative chemotherapy and IMRT were well tolerated with good clinical response and early clinical outcome. Pathological complete response predicts better outcomes. Prospective clinical trials with sufficient patient numbers and follow-up are needed to determine the true impact of IMRT in these patients.

Keywords: IMRT; Chemoradiation; Vulva

Article Outline

Introduction
Methods and materials
Simulation and target contouring
IMRT planning
Treatment schedule
Evaluation and statistics
Results
Toxicities
Discussion
References



Gynecologic Oncology
Volume 109, Issue 2, May 2008, Pages 291-295
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.